EOLS
Evolus, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$7.36
+3.66%Year over year
Reported trailing growth
- Revenue
- +13.9%
- EBITDA
- +78.0%
- EBIT
- +46.3%
- EPS
- +47.1%
- Free cash flow
- +58.2%
- Operating cash flow
- +62.8%
Forward estimates
Based on analyst estimates
- Revenue
- +20.2%
- EBITDA
- +757.1%
- EPS
- +149.4%
Three-year CAGR
- Revenue
- +26.0%
- EBITDA
- +9.9%
- EBIT
- -9.3%
- Net income
- -2.4%
- EPS
- +1.2%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026